Steve Dubin - 21 Jun 2026 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Reporting relationship: Director
Issuer ticker: ACET
Reported as of: 21 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 16:31:51 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Nick Harvey, Attorney-in-Fact

Key filing fact

Steve Dubin filed Form 4 for Adicet Bio, Inc. (ACET) on 23 Jun 2026.

Key facts

This page summarizes Steve Dubin's Form 4 filing for Adicet Bio, Inc. (ACET).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 16:31.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001265123 Primary reporting owner

DUBIN STEVE

Relationship: Director
Address: C/O ADICET BIO, INC., 131 DARTMOUTH STREET, FLOOR 3, BOSTON
Signature: /s/ Nick Harvey, Attorney-in-Fact
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACET transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +4,200
Change %
Price: $0.000000^*
Shares after: 4,200
Date: 21 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,200
Exercise price: $8.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.